LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
41.13
-1.06 (-2.51%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide.

The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories.

The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy.

The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers.

The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors.

LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

LivaNova PLC
LivaNova logo
CountryUnited Kingdom
Founded1987
IPO DateFeb 10, 1993
IndustryMedical Devices
SectorHealthcare
Employees2,900
CEOVladimir Makatsaria

Contact Details

Address:
20 Eastbourne Terrace
London, W2 6LG
United Kingdom
Phone44 20 3325 0660
Websitelivanova.com

Stock Details

Ticker SymbolLIVN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001639691
CUSIP NumberG5509L101
ISIN NumberGB00BYMT0J19
Employer ID98-1268150
SIC Code3845

Key Executives

NamePosition
Vladimir A. MakatsariaChief Executive Officer and Director
Alex Shvartsburg C.M.A.Chief Financial Officer
Michael D. HutchinsonSenior Vice President, Chief Legal Officer and Company Secretary
Ahmet Tezel Ph.D.Chief Innovation Officer
Franco PolettiPresident of Cardiopulmonary Business Unit
Lindsey LittleSenior Director of Investor Relations
Deanna WilkeVice President of Corporate Communications
Philip KowalczykChief Strategy and Corporate Development Officer
Natalia KozminaChief Human Resources Officer
Paul R. BuckmanPresident of Advanced Circulatory Support and GM of Transcatheter Mitral Valve Replacement

Latest SEC Filings

DateTypeTitle
Jul 18, 2025SCHEDULE 13G/AFiling
Jun 13, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 11, 20258-KCurrent Report
May 29, 2025SDForm - SD
May 21, 20258-KCurrent Report
May 13, 2025SCHEDULE 13G/AFiling
May 7, 2025IRANNOTICENotice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012
May 7, 202510-QQuarterly Report
May 7, 20258-KCurrent Report
Apr 30, 2025ARSFiling